AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 53 min read$PGNY

What To Expect From Progyny’s (PGNY) Q2 Earnings

Progyny (NASDAQ: PGNY) is set to report Q2 earnings after the market close. The article notes last quarter’s revenue of $328.5 million, up 1.4% year over year, and that guidance and EPS beat expectations. Q2 revenue is expected to rise 4.7% y/y. Analysts have largely reconfirmed estimates; average price target is $34 vs $31.66.

Original reporting
financialcontent.com
Published Aug 5, 2026, 5:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 5:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
What To Expect From Progyny’s (PGNY) Q2 Earnings — source image
Source · financialcontent.com
Decision brief

The 30-second read

$PGNYNeutralMed
01

Why it matters

Traders can use the consensus revenue growth rate (4.7% YoY) and the company’s recent pattern of missing revenue estimates to frame positioning into the print, but there is no incremental PGNY-specific disclosure in the text.

02

Market read

This is an earnings preview anchored to consensus expectations and peer read-through, not a new fundamental update.

03

What to watch

The article does not include any new PGNY guidance, margin/EBITDA details, or specific analyst revisions, so the setup may be less informative than it appears.

Relevance 4/10Novelty 4/10Timing: tomorrow after market close earnings release

Background

Progyny beat revenue expectations last quarter and is scheduled to report Q2 earnings tomorrow after the close.

Company-level read

Ticker impact

$PGNYNeutralMedium confidence
Context

Progyny is set to report Q2 results tomorrow after the close, with the article citing consensus revenue growth and recent estimate behavior.

Expected impact

Likely volatility around the after-close print versus the cited revenue growth expectations and any EBITDA/EPS commentary.

Evidence & confidence

The text frames what investors should expect (consensus growth, prior misses, peer results) rather than disclosing a fresh company-specific development.

Market effects

Sector

Peer read-through is used (CVS and Centene Q2 results), which can influence sentiment toward health insurance providers and managed care/fertility benefits.

Regional

Primarily US-focused equity sentiment around managed care and fertility benefits.

Global

Limited, as the catalyst is company-specific earnings timing and US peer results.

Counterpoint

What could challenge this read

If peers’ results were strong and the sector has been steady, PGNY could outperform despite its recent revenue-estimate misses.

Key entities

  • company
    Progyny

    Fertility benefits company scheduled to report Q2 earnings tomorrow after market close.

  • company
    CVS Health

    Peer cited for Q2 revenue growth and how the stock traded after results.

  • company
    Centene

    Peer cited for Q2 revenue growth and a post-results share decline.

Read at source← All news

Related articles

AUG 7
$PGNYMedAI 8/10

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.

financialcontent.com5 min
AUG 7
$PGNYMed

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.

yahoo.com3 min
AUG 6
$PGNYMed

Progyny, Inc. (PGNY): Results of Operations and Financial Condition

Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V

SEC EDGAR 8-K4 min
JUL 13
$PGNYMed

Progyny (PGNY) Stock Is Up, What You Need To Know

Progyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.

financialcontent.com4 min
MAY 31
$PGNYMedAI 8/10

A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000

Progeny (PGNY) director Kevin Gordon sold 5,500 shares for about $137,000, according to the article. The firm reported Q1 revenue of $328 million, up 1.4% YoY, with gross profit rising 10% to $83.1 million. It said client growth and retention were strong aside from a large client loss, and approved a $200 million share repurchase program.

finance.yahoo.com5 min